Pelin Secken

Dr. Pelin Secken

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2026 in Turkish Journal of Pediatric Disease
Verified
Journal Article
Open access
PDF file
SBSevim Ecem Ünlü Ballı
Sevim Ecem Ünlü Ballı
HSHatice Sürer
Hatice Sürer
PSPelin Secken
Pelin Secken
GBGökhan Berktuğ Bahadır
Gökhan Berktuğ Bahadır
GSGulcin Guler Simsek
Gulcin Guler Simsek
ISİlHami Sürer
İlHami Sürer
Objective: In failed cases treated with the endoscopic sub-ureteric injection method, no residue from the previous injection material was found during cystoscopy at the second injection. The clinical observation of an increased incidence of recurrent reflux in girls than in boys reminds us that bladder gender may influence the stability of the injection material. The aim of the study was to determine whether there is a gender-related difference in the durability of the subureteric injection material. Material and Methods: Twenty male and female Wistar-Albino rats were evenly divided into four groups. The experimental group received a submucosal injection of 0.1cc dextranomer hyaluronic acid copolymer (Dexell®) into the bladder. In addition, the control group received 0.1cc of 0.9% NaCl. Tissue hyaluronidase activity was measured biochemically using the ELISA method. The injection sites were assessed histopathologically and immunohistochemically with CD31 and CD34 Rabbit Monoclonal Antibodies. Results: Biochemically, tissue hyaluronidase activity in female groups was statistically significantly higher than in males. Histopathologically, there were no significant differences between the genders or between the experimental and control groups in relation to fibrosis formation. Regarding immunohistochemistry, angiogenesis was statistically significantly higher in all females, regardless of whether they were in the study or control group, compared to males. Concerning progenitor cell activity, there is no difference between the genders, whereas the difference between the study and control groups was significant. Conclusion: Biochemically, higher hyaluronidase activity in the female rat bladder may cause a faster breakdown of the hyaluronic acid compound in the injection material. The high permeability of inflammatory cells in the female rat bladder, as detected histochemically, may accelerate the destruction process with the aid of lytic enzymes in these cells.

22 March 2026 in Medicina
Verified
Journal Article
Open access
PDF file
KYKerim Bora Yilmaz
Kerim Bora Yilmaz
ETEce Tavukcuoglu
Ece Tavukcuoglu
HYHamdullah YANIK
Hamdullah YANIK
PSPelin Secken
Pelin Secken
ECErtugrul Celik
Ertugrul Celik
GEGunes Esendagli
Gunes Esendagli
Background and Objectives: A combination of chemotherapy and immunotherapy may improve cancer treatment outcomes; however, determining which patient groups will benefit from immunotherapy is critical. Triple-negative breast cancer (TNBC) achieves limited benefit from immune checkpoint inhibitors (ICIs) and anti-PD-L1 blockade therapy. Materials and Methods: In this study, PD-L1 expression levels in myeloid-derived cells in the tumor microenvironment were determined in an experimental TNBC model. Results: Compared with tumor cells, granulocytes, monocytes, and macrophages had significantly higher PD-L1 expression. CD206+ tumor-associated macrophages (TAMs) expressed the highest level of PD-L1. PD-L1 positivity in TAMs was also significantly high in the lung, liver, lymph node, and spleen. Despite treatment initiation in late-stage tumorigenesis, the combination of paclitaxel and the anti-PD-L1 monoclonal antibody atezolizumab significantly reduced tumor growth. In addition, lung metastasis burden was reduced with combined treatment compared with chemotherapy or anti-PD-L1 monotherapy alone. Conclusions: As a result, alterations in PD-L1+ myeloid cells and immune infiltration can be associated with atezolizumab and paclitaxel therapy success in triple-negative breast cancer.

8 February 2025 in American Journal of Reproductive Immunology
Verified
Journal Article
Closed access
ÇAÇAĞLAYAN ATEŞ
ÇAĞLAYAN ATEŞ
BDBerna Dilbaz
Berna Dilbaz
SESeval Yılmaz Ergani
Seval Yılmaz Ergani
PSPelin Secken
Pelin Secken
CKCaner Kose
Caner Kose